

Specialty Quantity Limit

Rasonque

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Rasonque	daraxonrasib

Program Description

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

Covered Quantities

Medication	Standard Limit	Exception Limit
Rasonque (daraxonrasib) 100 mg tablets	60 per 30 days	120 tablets per 30 days
Rasonque (daraxonrasib) 150 mg tablets	60 per 30 days	N/A

FDA-Recommended Dosing

300 mg once daily

Dosage reductions for adverse reactions:

- First dose reduction: 200 mg once daily
- Second dose reduction: 150 mg once daily

Reference number(s)
7598-H

Dosage modification for drug interactions:

- **Strong CYP3A inhibitors without P-gp inhibition:** Reduce Rasonque from 300 mg once daily to 150 mg once daily.
- **Moderate CYP3A inhibitors with P-gp inhibition:** Reduce Rasonque from 300 mg once daily to 100 mg once daily.
- **Moderate CYP3A inhibitors without P-gp inhibition:** Reduce Rasonque from 300 mg once daily to 200 mg once daily.
- **P-gp inhibitors:** Reduce Rasonque from 300 mg once daily to 150 mg once daily.
- **Strong CYP3A inducers:** Avoid concomitant use. If concomitant use cannot be avoided, increase Rasonque from 300 mg once daily to 400 mg once daily.
- **Moderate CYP3A inducers:** Increase Rasonque from 300 mg once daily to 400 mg once daily.

References

1. Rasonque [package insert]. Redwood City, CA: Revolution Medicines, Inc.; August 2026.